Takara Bio KK

4974

Equity

ISIN JP3460200003 / Valor 1986313

Tokyo Stock Exchange (2024-09-18)

JPY 1,005.00-1.37%

Takara Bio KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Takara Bio USA, Inc., operating under the umbrella of the Takara Bio Group, is a prominent entity in the life sciences sector, focusing on providing a comprehensive suite of products and services designed to facilitate research in gene discovery, regulation, and function. The company specializes in the development and distribution of kits, reagents, instruments, and services, aiming to accelerate scientific discovery in various fields, with a notable emphasis on oncology research. Takara Bio USA has recently introduced several innovative solutions to the market, including automated single-cell total RNA-seq and DNA-seq library preparation kits, the Shasta™ Single-Cell System for next-generation sequencing (NGS), and the Lenti-X Transduction Sponge, a novel tool for enhancing in vitro lentivirus-mediated gene delivery. These offerings underscore the company's commitment to providing high-quality, innovative tools that address the complex needs of researchers, particularly in the realm of oncology, where the company seeks to enable breakthroughs in biomarker discovery. As part of the global Takara Bio Group, which includes Takara Bio Europe and operates under brands such as Takara, Clontech, and Cellartis, Takara Bio USA leverages a leadership position in the global market to advance biotechnological research and improve the human condition.

Summarized from source with an LLMView SourceSector: Technology

Net Sales

For the three months ended June 30, 2024, Takara Bio KK reported net sales of ¥8,493 million, representing a 7.4% decrease compared to the same period in the previous year. This decline was primarily due to a reduction in sales of test-related products for new Coronavirus infectious diseases and a slump in the life science research market affected by the economic downturn overseas.

Operating Profit

Takara Bio KK experienced an operating loss of ¥1,634 million for the three months ended June 30, 2024. This is a significant decline from the operating profit of ¥423 million reported in the same period of the previous fiscal year. The increase in cost of sales and changes in the sales mix contributed to this operating loss.

Net Income

The net income attributable to owners of the parent for Takara Bio KK was a loss of ¥1,047 million for the three months ended June 30, 2024. This is a stark contrast to the net income of ¥319 million reported in the same period of the previous year. The decrease in operating income and ordinary income were key factors in this net loss.

Dividends

Takara Bio KK has announced that there will be no dividend payments for the first quarter of the fiscal year ending March 31, 2025. The forecast for the fiscal year-end dividend remains at ¥17.00 per share, consistent with the previous fiscal year.

Financial Forecast

For the fiscal year ending March 31, 2025, Takara Bio KK has forecasted net sales of ¥48,900 million, which represents a 12.4% year-on-year increase. The company also expects an operating profit of ¥5,200 million and net income attributable to owners of the parent of ¥3,400 million, indicating a significant recovery and growth compared to the previous fiscal year.

Summarized from source with an LLMView Source

Key figures

-29.0%1Y

-69.9%3Y

-56.9%5Y

Performance

34.6%1Y

29.5%3Y

34.0%5Y

Volatility